Theon acquires HGH Syst mes Infrarouges
Analysis based on 7 articles · First reported Jun 17, 2026 · Last updated Jun 17, 2026
The acquisition of HGH_Syst mes_Infrarouges by THEON International PLC is expected to be EBITDA margin accretive and mid-single-digit EPS accretive for THEON International PLC in 2027, indicating a positive financial outlook for the company. This strategic move will expand THEON International PLC's Multi-Domain ISR product portfolio and counter-drone solutions, potentially increasing its market share in the defense and security sectors.
THEON International PLC has entered into an exclusivity agreement with The Carlyle Group for the acquisition of SAS St rop es, the holding company of HGH_Syst mes_Infrarouges, for an enterprise value of approximately 300 million. HGH_Syst mes_Infrarouges specializes in electro-optical and infrared solutions for Defense and Civil applications, with a strong focus on R&D and proprietary AI technology. This acquisition is a key step in THEON International PLC's strategy to become a leader in platform electro-optics, broadening its Multi-Domain ISR product portfolio and counter-drone solutions. The transaction is expected to be financed by a bridge facility from BNP Paribas and is anticipated to be EBITDA margin and EPS accretive for THEON International PLC by 2027. The deal also reinforces THEON International PLC's commitment to France, establishing it as an important export hub and AI R&D center.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard